Brainstorm Cell Therapeutics Inc.

Good day, ladies and gentlemen, and welcome to the Brainstorm Cell Therapeutics second quarter 2021 earnings call. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Thomas Galassi. Sir, the floor is yours.

Good morning, and thank you for joining us. Before we begin the opening remarks, We would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders, such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2021 and beyond, the safety and clinical effectiveness of the Neurone Technology Platform, clinical trials of Neuron and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support their business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time to time in its SEC filings. The company's results may differ materially from those projected on today's call. The company undertakes no obligation to publicly update any forward-looking statements. Joining me on the call today will be Haim Leibowitz, President and CEO of BrainStorm, Dr. Ralph Kern, President and Chief Medical Officer, and Dr. Preetam Chah, Executive Vice President and CFO. In addition, Dr. Stacey Lindberg, Executive Vice President and Head of Global Clinical Research, and Dr. David Seppan, Executive Vice President and Chief Operating Officer, are also on the call and will be available to answer your questions during the Q&A session. Now I would like to turn the call over to Mr. Leibowitz. Please go ahead.

Thank you, Tom.